Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
The optimal duration of therapy for women with platinum-resistant ovarian cancer who respond to second-line treatment programs remains undefined. A patient with well-documented platinum-resistant ovarian cancer who responded to single-agent paclitaxel (175 mg/m2 over 3 hours q 28-35 days) was continued on this program for a total of 15 cycles delivered over a period of 16 months. The patient has subsequently remained without evidence of disease recurrence >7 years following discontinuation of this treatment regimen. The prolonged administration of paclitaxel, a highly cycle-specific cytotoxic agent, is a rational management option in patients with platinum-resistant ovarian cancer who exhibit evidence of a response to therapy and who do not experience excessive treatment-associated toxicity (e.g., grade 2-3 peripheral neuropathy).